1.	Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Phase: Phase IV Type: Prevention Status: Closed Age: 12 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 106636, NCT00534638
2.	Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: CDR0000441189, NCI-04-C-N191, NCI-590299/009, GSK-590299/009, NCT00128661
3.	Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 104772, NCT00250276
4.	Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Closed Age: 26 and older Sponsor: Pharmaceutical / Industry Protocol IDs: 104820, NCT00294047
5.	A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 35 Sponsor: Pharmaceutical / Industry Protocol IDs: 106001, NCT00306241
6.	Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Phase: Phase III Type: Natural history/Epidemiology, Prevention Status: Completed Age: 10 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 107476 (M18), 107477, 107479, 107481, NCT00337818
7.	Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women Phase: Phase III Type: Prevention Status: Completed Age: 18 to 35 Sponsor: Pharmaceutical / Industry Protocol IDs: 104479, NCT00344032
8.	Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 35 Sponsor: Pharmaceutical / Industry Protocol IDs: 105926, NCT00345878
9.	Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine Phase: Phase III Type: Natural history/Epidemiology, Prevention Status: Completed Age: 10 to 14 Sponsor: Pharmaceutical / Industry Protocol IDs: 104896 (month 18 FU), 104902, 104904, 104918, NCT00316706
10.	Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects Phase: Phase III Type: Natural history/Epidemiology, Prevention Status: Completed Age: 11 to 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 107682, NCT00369824
11.	Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 to 45 Sponsor: Pharmaceutical / Industry Protocol IDs: 108933, NCT00423046
12.	Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects Phase: Phase III Type: Prevention Status: Completed Age: 10 to 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 108464, NCT00426361
13.	Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years Phase: Phase III Type: Prevention Status: Completed Age: 26 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 109801, NCT00456807
14.	Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 10 - 25 Years of Age. Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 10 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 106069, NCT00481767
15.	A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 15 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 107291, NCT00485732
16.	Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 10 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 110168, NCT00492544
17.	Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 15 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 109179, NCT00552279
18.	Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects Phase: Phase III Type: Natural history/Epidemiology, Prevention Status: Completed Age: 9 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 110886, NCT00578227
19.	Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299) Phase: Phase III Type: Prevention Status: Completed Age: 20 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 111567, NCT00637195
20.	Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 9 to 15 Sponsor: Pharmaceutical / Industry Protocol IDs: 111507, NCT00652938
21.	Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 Phase: Phase III Type: Prevention Status: Completed Age: 15 to 55 Sponsor: Pharmaceutical / Industry Protocol IDs: 103514, 105879, 105880, 105881, 105882, NCT00196937
22.	Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects Phase: Phase III Type: Prevention Status: Closed Age: 18 to 25 Sponsor: Pharmaceutical / Industry Protocol IDs: 107638, NCT00779766
23.	Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US Phase: Phase III Type: Prevention Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111955, NCT00799825
24.	Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects. Phase: Phase III Type: Prevention Status: Completed Age: 25 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111712, NCT00811798
25.	Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand Phase: Phase III Type: Prevention Status: Closed Age: 26 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 111758, NCT00849381